Evaluation of Diabetes Drug Safety

A hearing was held on the role of the Food and Drug Administration in evaluating the safety of Avandia, a drug used in the treatment of… read more

A hearing was held on the role of the Food and Drug Administration in evaluating the safety of Avandia, a drug used in the treatment of Type 2 diabetes. FDA officials testified about post-marketing surveillance of new drugs and “meta-analysis.” Avandia was approved by the FDA in 1999. Dr. Nissen testified about his study linking Avandia use with a 43 percent increased risk of heart attack. Dr. Buse testified about increased cholesterol in Avandia-using patients. Witnesses emphasized the need for earlier studies and more sensitive protocols. Dr. Slaoui testified about GlaxoSmithKline’s research and actions.

Dr. Buse is also the president-elect for medicine and science of the American Diabetes Association. close

*The transcript for this program was compiled from uncorrected Closed Captioning.

People in this video

  • Buse, John B. M.D. Chief University of North Carolina at Chapel Hill->Division of Endocrinology
  • Dal Pan, Gerald Director U.S. Food and Drug Administration->Office of Surveillance and Epidemiology
More People

Hosting Organization

More information about

Evaluation of Diabetes Drug Safety

210 Views
Program ID:
198496-1
Category:
House Committee
Format:
House Committee
Location:
Washington, District of Columbia, United States
First Aired:
Jun 7, 2007
Last Aired:
Jun 8, 2007

Airing Details

  • Jun 07, 2007 | 12:43am EDT | C-SPAN 2
  • Jun 08, 2007 | 2:56pm EDT | C-SPAN 2
  • Jun 08, 2007 | 9:35pm EDT | C-SPAN 2
Purchase a DVD or Download

Evaluation of Diabetes Drug Safety

  • DVD
    Length:
    03:58:38
    Price:
    $29.95
    Add to Cart
  • MP4 video - Standard
    Request Download
  • MP4 video - Low
    Request Download
  • MP3 audio
    Length:
    03:58:38
    Price:
    $0.99
    Add to Cart

Clips from This Video